PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27877174-6	2016	The analysis of cytokine production revealed that CD4+CD25- T cells with 5-Aza treatment produced comparable levels of interferon (IFN)-gamma and transforming growth factor (TGF)-beta, but less IL-10 and more IL-2, when compared to cells without 5-Aza treatment.	Azacitidine	73-78	interleukin 2 receptor subunit alpha	Homo sapiens	54-58	
27877174-3	2016	We report that the combination of the DNA methyltransferase inhibitor 5-azacytidine (5-Aza) and suboptimal T cell receptor (TCR) stimulation promoted CD4+CD25hFOXP3+ T cell induction from human CD4+CD25- T cells.	Azacitidine	70-83	interleukin 2 receptor subunit alpha	Homo sapiens	154-158	
27877174-3	2016	We report that the combination of the DNA methyltransferase inhibitor 5-azacytidine (5-Aza) and suboptimal T cell receptor (TCR) stimulation promoted CD4+CD25hFOXP3+ T cell induction from human CD4+CD25- T cells.	Azacitidine	85-90	interleukin 2 receptor subunit alpha	Homo sapiens	154-158	
27877174-4	2016	5-Aza treatment enhanced the expression of Treg cell signature genes, such as CD25, FOXP3, CTLA-4, and GITR, in CD4+CD25h cells.	Azacitidine	0-5	interleukin 2 receptor subunit alpha	Homo sapiens	78-82	
27877174-6	2016	The analysis of cytokine production revealed that CD4+CD25- T cells with 5-Aza treatment produced comparable levels of interferon (IFN)-gamma and transforming growth factor (TGF)-beta, but less IL-10 and more IL-2, when compared to cells without 5-Aza treatment.	Azacitidine	246-251	interleukin 2 receptor subunit alpha	Homo sapiens	54-58	
24583533-0	2014	Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine.	Azacitidine	121-132	interleukin 2 receptor subunit alpha	Homo sapiens	14-18